Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2018 / Article

Research Article | Open Access

Volume 2018 |Article ID 9363868 | 7 pages | https://doi.org/10.1155/2018/9363868

Potential Antiproliferative Activity and Evaluation of Essential Oil Composition of the Aerial Parts of Tamarix aphylla (L.) H.Karst.: A Wild Grown Medicinal Plant in Jordan

Academic Editor: Mohammed S. Ali-Shtayeh
Received11 Mar 2018
Revised04 May 2018
Accepted16 May 2018
Published21 Jun 2018

Abstract

Essential (volatile) oil from aerial parts of Tamarix aphylla (L.) H.Karst. (Tamaricaceae) grown wild in Jordan was hydrodistilled by Clevenger apparatus and analyzed by means of GC and GC-MS techniques. In vitro screening of potential cytotoxicity of the aqueous (AE) and ethanol (EE) extracts was also evaluated against human breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (Caco-2), and pancreatic carcinoma (Panc-1) cancer cell lines as well as normal human fibroblasts. GC-MS analysis of T. aphylla EO revealed its richness in nonterpenoid nonaromatic hydrocarbons (52.39%), with predominance of 6,10,14-trimethyl-2-pentadecanone as the principal component. Biologically, the plant extracts exhibited cytotoxicity effects in dose-dependent manner against most of the tested cell lines, but potent effects were only predicted against MCF-7 cells with IC50 values of 2.17 ± 0.10 and 26.65 ± 3.09 μg/mL for T. aphylla AE and EE, respectively. T. aphylla AE demonstrated a comparable cytotoxic effect with that offered by the control drug cisplatin (IC50 value of 1.17 ± 0.13 μg/mL), even with higher safety profile against normal fibroblast cells (IC50 values of T. aphylla AE versus cisplatin: 79.99 ± 4.90 versus 9.08 ± 0.29 μg/mL). T. aphylla extracts could be a valuable source for cytotoxic agents with high safety and selective cytotoxicity profiles. Unfortunately, no antiproliferative potential against Caco-2 or Panc-1 cancer cell lines was detected at a concentration less than 30 μg/mL.

1. Introduction

Jordan’s flora is rich in a wide variety of medicinal plants and hence is widely utilized by Jordanians for health maintenance. It is believed that the ease of access to herbal remedies alongside their wide safety margins encourages their usage by patients [1]. Recently, many efforts have been exerted to find out the potential roles of different medicinal plants in cancer treatment. Despite the fact that many of the widely grown plants in Jordan have been screened for their antiproliferative activities [2], many others either are under current investigation or are still unevaluated.

Tamarix aphylla (L.), which is known as ‘Tamarisk’ or ‘Athel’ in Jordan, is an evergreen tree with tiny, triangular, and scale-like leaves. It grows in dense groves and it flourishes in high alkalinity-salinity soils. Tamarisk is native throughout the Middle East across East, North, and Central Africa and to a little extent into parts of Western and Southern Asia [3]. Many communities have used T. aphylla in traditional medicine. Its leaves were used for wounds and abscess healing, as astringent, and for rheumatism and joint pain [4, 5]. Several studies have recognized the various types of secondary metabolites present in T. aphylla. Reports had identified the presence of flavonoids [6], phenolics [7], hydrolysable tannins [3], and alkaloids [7, 8] in the plant various extracts. Earlier investigations on the effects of T. aphylla on biological systems had revealed its insect growth inhibitory activity due to presence of ellagic acid [9]. The isolated isoferulic acid derivative, aphyllin, was also shown to exhibit a distinct radical scavenging activity and to improve the viability of human keratinocytes [10]. In Saudi Arabia, alcohol extract from leaves of T. aphylla was shown to possess antioxidant, anti-inflammatory, and wound-healing activities. The authors suggested that the presence of known active phytochemicals like flavonoids and polyphenols explains these reported effects [11]. The plant was also reported to exhibit analgesic and antipyretic activities [12].

Several previous studies have investigated the potential roles of various T. aphylla extracts in the prevention and/or treatment of many ailments [5, 11, 12]; nevertheless, only few researches have focused on investigating its volatile essential oil (EO) composition or evaluating the plant’s antiproliferative effects against selected cancer cell lines. In this present study, the EO hydrodistilled from aerial parts of wild grown Jordanian species of T. aphylla was analyzed by gas chromatography-mass spectrometry (GC-MS) for purpose of chemical composition analysis. In vitro cytotoxic activities of the aqueous extract (AE) and ethanol extract (EE) against human colorectal adenocarcinoma (Caco-2), breast adenocarcinoma (MCF-7), and pancreatic carcinoma (Panc-1) cancer cell lines alongside normal human fibroblasts were also assessed. Interestingly, this is the first time that the EO composition and the cytotoxic activities of T. aphylla aerial parts are evaluated.

2. Materials and Methods

2.1. Phytochemical Analysis
2.1.1. Plant Material

About 650 g of the aerial parts of T. aphylla (L.) H.Karst. was collected from north Amman in May 2016. Collected parts were taxonomically identified by Professor Khaled Tawaha (School of Pharmacy, the University of Jordan) and then set to air-dry under shade in a cool place for further study. Voucher specimen has been deposited in the Department of Pharmaceutical Sciences, School of Pharmacy, the University of Jordan, and given a specimen ID (TA-Hudaib-MAY16-001).

2.1.2. Preparation of Crude Plant Extracts

Both the aqueous and ethanol extracts of the dried plant aerial parts were prepared by maceration. Separately, a powdered 100 g quantity was placed in round-bottomed flask and either a 1 L of 70% ethanol (EtOH) or 1 L distilled water was added in a ratio of 1:10. Flasks were kept for one week in a cool place; the filtrates were collected and then dried using rotary evaporator at 40°C. The dried extracts were kept in tightly closed flasks, at 4°C, for subsequent analysis.

2.1.3. TLC

Thin layer chromatography (TLC) was performed (in duplicate) to obtain qualitative fingerprinting of the prepared crude extracts. TLC was achieved on precoated TLC silica gel plates (ALUGRAM SIL G/UV254, Macherey-Nagel GmbH & Co., Germany), using different mobile phases. Detection of chemical constituent was conducted as reported by Wagner and Bladt [14].

2.1.4. Essential Oil Extraction

300 g of dried aerial parts of T. aphylla was soaked in 2.5 L of distilled water and then hydrodistilled for 2 hours using Clevenger-type apparatus. The hydrodistilled EO was collected using GC grade n-hexane, dried over anhydrous sodium sulphate, and then kept in tightly closed vial, at 4°C, until analysis.

2.1.5. GC-MS Analysis

GC-MS analysis of EO was performed in duplicate after appropriate dilution of the hydrodistilled oil in GC grade n-hexane. Around 1 μL aliquot of the diluted oil was injected into a split-splitless injector of a Varian Chrompack CP_3800 GC/MS/MS-200 (Saturn, Netherlands) GC-MS outfitted with DB-5 (5% diphenyl, 95% dimethyl polysiloxane) capillary column (30 m length x 0.25 mm ID, 0.25 μm film thickness). The injector temperature was kept at 250°C with a split ratio of 1:10 and Helium was used as a carrier gas with a flow rate of 1 mL/minute. The column temperature was programmed to be initially isothermal at 60°C for 1 minute and then to increase up to 246°C at a rate of 3°C/minute and then to be kept isothermal at 246°C for 3 minutes for a total run time of about 66 min. The MS ionization source temperature was 180°C with an ionization voltage of 70 eV.

2.1.6. GC-FID Analysis

Quantitative analysis of the hydrodistilled oil (performed in duplicate) was carried out using a Focus GC (Thermo Electron Corporation) gas chromatograph equipped with fused silica capillary column OPTIMA-5 (5% diphenyl 95% dimethyl polysiloxane; 30 m length × 0.25 mm ID, 0.25 μm film thickness). The column was coupled to an injector (split-splitless type) and flame-ionization detector (FID). The same temperature program was used as mentioned above in GC-MS analysis section. Injector temperature was maintained at 250°C with split ratio of 1:50, while FID temperature was held at 300°C. Percent content (% w/w) of each component was calculated using its corresponding normalized relative area obtained by FID and assuming a unity response by all components [15].

2.1.7. EO Component Identification

Qualitatively, identification of volatile components was carried out using built-in libraries (e.g., Wiley, Terpenes, NIST, and Adams’ libraries). A comparison of the calculated Arithmetic Retention Index (RI) of each identified component with literature reference value measured with a column of identical polarity alongside MS spectrum matching helped to confirm the identification [15]. RIs of EO components were calculated relative to n-alkane hydrocarbons (C8-C20) analyzed under the same chromatographic conditions, as above, using the modified arithmetic equation by Van Den Dool and Kratz [16]. Quantitatively, the % content of each EO component was measured as mentioned above in GC-FID section.

2.2. In Vitro Cytotoxicity
2.2.1. Cell Culture

Three different adherent cancer cell lines, named MCF-7 (ATCC: HTB-22™), Caco-2 (ATCC: HTB-37™), and Panc-1 (ATCC: CRL-1469™) cells, were used for testing the antiproliferative activity. Normal periodontal fibroblast cell line (provided from School of Dentistry, University of Jordan, Jordan) was used for testing selective toxicity of reference drugs and the different extracts. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Caisson Laboratories Inc., USA) at 37°C. Cells dilution with medium to give optimal plating densities (determined by the supplier for each cell line) was carried out before they were plated in 96-well plates.

2.2.2. Extracts and Reference Drugs Pretreatment for Cytotoxicity Assay

Each extract (10 mg) was weighed accurately and dissolved in 1 mL solvent. Solvents used were dimethyl sulfoxide (DMSO, tissue culture grade, Merck Schuchardt, Germany) for EE and DMEM for AE. Doxorubicin and cisplatin (both EBEWE Pharma GMBH Nfg. KG, Austria) were used as positive control drugs. Proper dilutions were made to achieve increasing concentrations of both extracts (0.1–800 μg/mL) and positive controls (0.1–200 μg/mL).

2.2.3. Cytotoxicity Assay

Increasing concentrations of extracts and control drugs were added to the plated cells. Each concentration was added in 3 replicates for each test material and the test was repeated 3 times independently. The different concentrations used for EtOH extracts contain no more than 2% of solvent DMSO. As indicated in previous studies [17], plates were incubated for 72 hours. Once the exposure time had finished, cells growth was analyzed using tetrazolium reduction (MTT) assay as described by Riss [18]. Absorbance was read by multiwell plate reader (Bio-Tek Instrument, USA) at 570 nm using a reference wavelength of 630 nm.

2.2.4. IC50 Value Calculation

As described by (1) and (2), percent cytotoxicity at each concentration was calculated from the obtained optical density (OD) by the plate reader. Before any further interpretation, all data were blank-adjusted. As described by (3), equations obtained from the logarithmic plot of % cytotoxicity versus concentration (μg/mL) were used to calculate IC50.

3. Results

3.1. TLC

TLC tests revealed the presence of different secondary metabolites in tested T. aphylla extracts as shown in Table 1. TLC chromatograms pointed out the presence of flavonoids as the major components in both extracts. Minor fractions of terpenoids were only detected in the ethanol extract, while coumarins were presented in both extracts.


SampleFlavonoidsCoumarinsAlkaloidsTerpenoids

T. aphylla AE++++-----------
T. aphylla EE++++-----+

AE: aqueous extract; EE: ethanol extract.
3.2. Oil Composition

The GC-MS chromatogram of the hydrodistilled EO from T. aphylla aerial parts alongside the main identified components is shown in Figure 1. Many volatile principles that have been identified are presented in Table 2. As shown, the GC-MS analysis of T. aphylla EO resulted in the identification of 33 components predominated mainly by 6,10,14-trimethyl-2-pentadecanone as the principal component (32.39%) and β-ionone (13.74%) and dodecanoic acid (6.00%) as major ones. The majority of the volatile constituents which are classified as oxygenated nonterpenoid nonaromatic hydrocarbons (52.39%) were mainly containing, in addition to the principal component, dodecanoic acid (6.00%), tetradecanoic acid (3.35%), and tridecanal (2.39%). The prevalence of oxygenated sesquiterpenes is quite high (26.53%), with predominance of β-ionone (13.74%), 5E,9E-farnesyl acetone (2.82%), α-muurolen-15-al (2.27%), and 14-OH-9-epi-E-caryophyllene (2.16%). On the other hand, neryl acetone (2.82%) represented the main monoterpenes identified in T. aphylla essential oil.


No.Rt.RI Lit.RI Exp.Compound% content

18.97110221021o-cymeneTr.
210.20410541053γ-terpinene0.37
312.06910991102cis-decahydronaphthalene1.44
412.15211011104α-thujone0.57
516.36912001203cis-4-caranone0.63
616.89912171215β-cyclocitral0.31
721.284131513162E,4E-decadienal0.67
823.75713731374β-E-damascenone0.81
925.09914081406dodecanal1.35
1026.61914441443neryl acetone2.82
1127.85614771473-ionone13.74
1228.05114891478cis-eudesma-6,11-diene0.32
1329.25115081508farenal1.02
1429.39915091512tridecanal2.39
1529.65615211518β-sesquiphellandrene1.20
1631.42315651563dodecanoic acid6.00
1731.80715791573n-hexyl benzoate1.69
1833.19616111609tetradecanal0.75
1935.3241668166614-OH-9-epi-E-caryophyllene2.16
2035.567167216735-isocedranol0.81
2136.0116851685ishwarone0.76
2236.45417001697n-heptadecane0.92
2336.972171317112E,6Z-farnesal0.74
2438.818NA1763tetradecanoic acid3.35
2538.97117671768α-muurolen-15-al2.27
2639.99618001797octadecane0.97
2740.561181618132E,6E-farnesoic acid0.57
2841.4241845g18396,10,14-trimethyl-2-pentadecanone32.39
2942.776188618795E,9Z-farnesyl acetone1.64
3043.38119001897nonadecane1.07
3143.624191319045E,9E-farnesyl acetone2.82
3243.932NA191314Z-Methyl-8-hexadecenal2.48
3344.17719211921methyl hexadecanoate0.72
Monoterpenes (MT)7.62
Hydrocarbon MT: No. 1-31.81
Oxygenated MT: No. 4-8,105.81
Sesquiterpenes (ST)28.05
Hydrocarbon ST: No. 12,151.52
Oxygenated ST: No. 11,13,19-21,23,25,27,29,3126.53
Nonterpenoid nonaromatic compounds: No. 9,14,16,18,22,24,26,28,30,32,3352.39
Nonterpenoid aromatic compounds: No. 171.69
Total Identified %89.75

Notes: compounds are listed in order of their elution times from a DP-5 column. : retention time; : literature RI13; : experimental RI relative to (C8-C20) n-alkanes; : the percentage composition based on peaks areas; : traces: below 0.1 % content; : RI value not available in literature; : reference [13]. Compounds in bold are the major (≥ 4%).
3.3. Cytotoxicity Evaluation

Table 3 demonstrates the in vitro calculated IC50 values (μg/mL) of T. aphylla AE and EE as well as control drugs (cisplatin and doxorubicin). The in vitro cytotoxicity profiles (% cytotoxicity versus concentration) of the control drugs alongside the different tested extracts are shown in Figures 25. Regarding the EO, the amount obtained by hydrodistillation unfortunately hindered its further biological evaluation due to presence in traces.


TreatmentCytotoxicity (IC50 value: mean ± SD; μg/mL)
MCF-7Caco-2Panc-1PDL Fibroblasts

Doxorubicin0.01 ± 0.0010.10 ± 0.010.06 ± 0.010.14 ± 0.02
Cisplatin1.17 ± 0.131.11 ± 0.155.97 ± 0.579.08 ± 0.29
T. aphylla AE2.17 ± 0.10479.76 ± 54.99Nontoxic79.99 ± 4.90
T. aphylla EE26.65 ± 3.09130.55 ± 12.2588.74 ± 2.44154.90 ± 3.29

Notes. Nontoxic within the investigated concentration range (0.1–800 μg/mL). AE: aqueous extract; EE: ethanol extract.

The American National Cancer Institute (NCI) guidelines set the limit of activity for crude plants extracts at 50% inhibition (IC50) of proliferation to be < 30 μg/mL after the exposure time of 72 hours [19]. Accordingly, it appears that T. aphylla AE and EE are potentially potent cytotoxic extracts against MCF-7 cell line, with IC50 values (μg/mL) of 2.17 ± 0.10 and 26.65 ± 3.09, respectively. Doxorubicin and cisplatin’s respective IC50 values against MCF-7 cells are 0.01 ± 0.001 and 1.17 ± 0.13. Both extracts unfortunately lacked cytotoxic potential against Panc-1 or Caco-2 cell lines in the tested concentration range. Regarding the safety profile on normal fibroblasts, both extracts of T. aphylla demonstrated higher safety compared with doxorubicin and cisplatin. Figures 25 illustrate the different effects of the tested extracts and control drugs.

4. Discussion

Preliminary TLC test revealed the presence of flavonoids in both T. aphylla AE and EE, which was previously described by other researches [6]. The main identified volatile principle, 6,10,14-trimethyl-2-pentadecanone, is a nonaromatic oxygenated hydrocarbon (ketone) and has a slightly fatty aroma with reported antimicrobial [20] and antioxidant [21] properties. Other main identified compounds were β-ionone (13.74%) and dodecanoic acid (6.00%). Oxygenated sesquiterpenes account for almost 27% of the identified oil. Different compositions of the EO from different Tamarix species were also reported in literature. As described by Orfali [22], bicyclooctan-2-one was found to be the major compound (46.09%) in T. nilotica of Saudi Arabia. Hexadecanoic acid methyl ester was reported as the major principle in T. chinensis fruit [23]. Hexadecanoic acid (in aerial parts and stems), 2,4-nonadienal (in flowers), and germacrene D (in leaves) were, however, reported as majors of T. boveana [24]. Like in T. chinensis, nonaromatic hydrocarbons resembled the abundant group of T. aphylla aerial parts, while fatty acids and fatty esters are the majors in T. boveana leaves [24]. On the other hand, among terpenes, oxygenated and hydrocarbon sesquiterpenes are prevalent in T. aphylla and T. boveana [24], respectively.

Biologically, several previous studies were also performed on the different species of Tamarix. In the current study, both the AE and EE of T. aphylla showed an interesting cytotoxic effect against MCF-7 cells. According to NCI guidelines [19], the selective cytotoxicity of T. aphylla AE (IC50 value of 2.17 ± 0.10 μg/mL) against MCF-7 cells proved to be comparable to that of cisplatin (IC50 value of 1.17 ± 0.13 μg/mL) and even with higher safety as revealed by their relative IC50 values on fibroblast cells (IC50 (μg/mL): 79.99 ± 4.90 for AE versus 9.08 ± 0.29 for cisplatin). Despite the higher IC50 values on fibroblast cells compared with doxorubicin and cisplatin, both extracts unfortunately lacked cytotoxic potential against Panc-1 or Caco-2 cell lines in the tested concentration range.

On the other hand, recent study on methanol extract of T. aphylla had investigated its potential cytotoxicity using brine shrimp method and revealed 70% mortality rate at concentration of 500 μg/ml [25]. In other studies, different extract of T. nilotica was tested against mouse lymphoma, rat hepatoma, and rat glioma cell lines. Interestingly, it was the presence of potent anticancer agents in the alcohol extract that could result in a powerful cytotoxic effect with % survival of 58.9 at 10 μg/mL [22]. Also, T. africana shoot extract inhibited the growth of A-549 lung carcinoma cells, with an IC50 value of 34 μg/mL [26]. Previous reports of phytochemical screening of T. aphylla revealed its high content of flavonoids, polyphenols, and tannins [3, 6, 8]. Several phenolic compounds isolated from Tamaricaceae were tested for their cytotoxic effects against different cancer cell lines and were shown to exhibit cytotoxic potentials [27]. Of these compounds are ferulic acid derivatives. Aphyllin, the isolated glycosylated isoferulic acid, exhibited a distinct radical scavenging activity and was found to improve the viability of human keratinocytes [10]. Ellagitannins were also reported to exhibit significant host-mediated antitumor and remarkable antiangiogenic activities [28]. Tamarixetin was also found to be cytotoxic against leukemia cells [29]. This latter compound inhibited proliferation in a concentration- and time-dependent manner, induced apoptosis, and blocked cell cycle progression. Syringic acid, a natural phenolic compound with selective antimitogenic activity on human malignant melanoma cells, was recently isolated from the methanol extract of T. aucheriana [30]. Methyl ferulate from T. aucheriana demonstrated cytotoxic and chemo-sensitizing effects [31], while glucuronosylated flavonoids from T. gallica aerial part were shown to prevent amyloid aggregation [32]. The potent cytotoxic activity observed for the tested extracts of T. aphylla under study is potentially attributed to presence of such compounds belonging principally to the phenolic fraction and other secondary metabolites as revealed by the TLC tests (Table 1).

5. Conclusion

The presence of different secondary metabolites with different biological activities renders medicinal plants valuable in drug discovery. Many biological activities have been linked to specific chemical entities present in the plants, such as flavonoids, tannins, polyphenols, and other compounds. The data obtained in this study suggest that different extracts of T. aphylla have potential antiproliferative activities against MCF-7 cancer cell line, which could be a source of promising lead compounds for the development of new treatments for some cancer types.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this manuscript.

Acknowledgments

The authors wish to acknowledge the Deanship of Academic Research & Quality Assurance at the University of Jordan for funding. They also wish to acknowledge School of Pharmacy at University of Jordan for the provided support.

References

  1. M. S. Ali-Shtayeh, R. M. Jamous, and R. M. Jamous, “Herbal preparation use by patients suffering from cancer in Palestine,” Complementary Therapies in Clinical Practice, vol. 17, no. 4, pp. 235–240, 2011. View at: Publisher Site | Google Scholar
  2. F. U. Afifi-Yazar, V. Kasabri, and R. Abu-Dahab, “Medicinal plants from jordan in the treatment of cancer: Traditional uses vs in vitro and in vivo evaluations part 1,” Planta Medica, vol. 77, no. 11, pp. 1203–1209, 2011. View at: Publisher Site | Google Scholar
  3. M. A. A. Orabi, M. Yoshimura, Y. Amakura, and T. Hatano, “Ellagitannins, gallotannins, and gallo-ellagitannins from the galls of Tamarix aphylla,” Fitoterapia, vol. 104, pp. 55–63, 2015. View at: Publisher Site | Google Scholar
  4. S. K. Marwat, M. A. Khan, M. A. Khan et al., “Salvadora persica, Tamarix aphylia and Zizyphus mauritiana - Three woody plant species mentioned in Holy Quran and Ahadith and their ethnobotanical uses in north western part (D.I. Khan) of Pakistan,” Pakistan Journal of Nutrition, vol. 8, no. 5, pp. 542–547, 2009. View at: Publisher Site | Google Scholar
  5. A. Mahfoudhi, C. Grosso, R. F. Gonçalves et al., “Evaluation of antioxidant, anti-cholinesterase, and antidiabetic potential of dry leaves and stems in Tamarix aphylla growing wild in Tunisia,” Chemistry Biodiversity, vol. 12, pp. 1747–1755, 2016, https://www.ncbi.nlm.nih.gov/labs/journals/chem-biodivers/. View at: Google Scholar
  6. M. A. El Ansari, M. A. M. Nawwar, A. El Dein, A. El Sherbeiny, and H. I. El Sissi, “A sulphated kaempferol 7,4-dimethyl ether and a quercetin isoferulylglucuronide from the flowers of Tamarix aphylla,” Phytochemistry, vol. 15, no. 1, pp. 231-232, 1976. View at: Publisher Site | Google Scholar
  7. A. M. A. Souliman, H. H. Barakat, A. M. D. El-Mousallamy, M. S. A. Marzouk, and M. A. M. Nawwar, “Phenolics from the bark of Tamarix aphylla,” Phytochemistry, vol. 30, no. 11, pp. 3763–3766, 1991. View at: Publisher Site | Google Scholar
  8. H. S. Yusufoglu, A. Alam, and A. Al-Howeemel, “Pharmacognostic and preliminary phytochemical standardization of Tamarix aphyllaand Ziziphus nummulariagrowing in Saudi Arabia,” Asian Journal of Biological and Life Sciences, vol. 1, pp. 42–46, 2015. View at: Google Scholar
  9. J. A. Klocke, B. Van Wagenent, and M. F. Balandrin, “The ellagitannin geraniin and its hydrolysis products isolated as insect growth inhibitors from semi-arid land plants,” Phytochemistry, vol. 25, no. 1, pp. 85–91, 1985. View at: Publisher Site | Google Scholar
  10. M. A. M. Nawwar, S. A. M. Hussein, N. A. Ayoub et al., “Aphyllin, the first isoferulic acid glycoside and other phenolics from Tamarix aphylla flowers,” Die Pharmazie, vol. 64, no. 5, pp. 342–347, 2009. View at: Publisher Site | Google Scholar
  11. H. S. Yusufoglu and S. I. Alqasoumi, “Anti-inflammatory and wound healing activities of herbal gel containing an antioxidant tamarix aphylla leaf extract,” International Journal of Pharmacology, vol. 7, no. 8, pp. 829–835, 2011. View at: Publisher Site | Google Scholar
  12. M. I. Qadir, K. Abbas, R. Hamayun, and M. Ali, “Analgesic, anti-inflammatory and anti-pyretic activities of aqueous ethanolic extract of Tamarix aphylla L. (Saltcedar) in mice,” Pakistan Journal of Pharmaceutical Sciences, vol. 27, no. 6, pp. 1985–1988, 2014. View at: Google Scholar
  13. K. Morteza-Semnani, M. Saeedi, and M. Akbarzadeh, “Essential oil composition of Teucrium scordium L.,” Acta Pharmaceutica, vol. 57, no. 4, pp. 499–504, 2007. View at: Publisher Site | Google Scholar
  14. H. Wagner and S. Bladt, Plant Drug analysis: A Thin Layer Chromatography Atlas, Springer, 2nd edition, 1996.
  15. R. P. Adams, Identification of Essential Oil Components by Gas Chromatography/Mass Spectroscopy, Allured, Carol Stream, Ill, USA, 4th edition, 1995. View at: Publisher Site
  16. H. van Den Dool and P. Dec. Kratz, “A generalization of the retention index system including linear temperature programmed gas—liquid partition chromatography,” Journal of Chromatography A, vol. 11, pp. 463–471, 1963. View at: Publisher Site | Google Scholar
  17. V. Kasabri, F. U. Afifi, R. Abu-Dahab et al., “In vitro modulation of metabolic syndrome enzymes and proliferation of obesity related-colorectal cancer cell line panel by salvia species from jordan,” Revue Roumaine de Chimie, vol. 59, no. 8, pp. 693–705, 2014. View at: Google Scholar
  18. T. L. Riss, “Assay Guidance Manual,” ELC and NCATS, p. 31, 2013. View at: Google Scholar
  19. V. Kuete, A. G. Fankam, B. Wiench, and T. Efferth, “Cytotoxicity and modes of action of the methanol extracts of six cameroonian medicinal plants against multidrug-resistant tumor cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 285903, 10 pages, 2013. View at: Publisher Site | Google Scholar
  20. P. Iyapparaj, P. Revathi, R. Ramasubburayan et al., “Antifouling and toxic properties of the bioactive metabolites from the seagrasses Syringodium isoetifolium and Cymodocea serrulata,” Ecotoxicology and Environmental Safety, vol. 103, no. 1, pp. 54–60, 2014. View at: Publisher Site | Google Scholar
  21. C. Xu, S. Zhao, M. Li, Y. Dai, L. Tan, and Y. Liu, “Chemical composition, antimicrobial and antioxidant activities of essential oil from flue-cured tobacco flower bud,” Biotechnology & Biotechnological Equipment, vol. 30, no. 5, pp. 1026–1030, 2016. View at: Publisher Site | Google Scholar
  22. R. S. Orfali, “Phytochemical and Biological Study of Tamarix nilotica growing,” in in Saudi Arabia. MSc. thesis, King Saud University, Riyadh, 2005. View at: Google Scholar
  23. M. Mahemuti, H. Miliban, and W. Mearhaba, “Analysis of volatile oil and fatty acids in Tamarix chinensisfruit,” Chinese Journal of Applied Chemistry, vol. 2, pp. 239–244, 2015. View at: Google Scholar
  24. D. Saïdana, M. A. Mahjoub, O. Boussaada et al., “Chemical composition and antimicrobial activity of volatile compounds of Tamarix boveana (Tamaricaceae),” Microbiological Research, vol. 163, no. 4, pp. 445–455, 2008. View at: Publisher Site | Google Scholar
  25. H. Muhammad, S. M. Wazir, and R. A. Khan, “In Vitro Antioxidant, Antifungal and Cytotoxic Activities of Selected Medicinal Plants of District Bannu and Lakki Marwat,” Studies on Ethno-Medicine, vol. 11, pp. 226–232, 2017. View at: Google Scholar
  26. M. Karker, N. De Tommasi, A. Smaoui, C. Abdelly, R. Ksouri, and A. Braca, “New sulphated flavonoids from tamarix africana and biological activities of its polar extract,” Planta Medica, vol. 82, no. 15, pp. 1374–1380, 2016. View at: Publisher Site | Google Scholar
  27. M. A. Nawwar, N. F. Swilam, A. N. Hashim, A. M. Al-Abd, A. B. Abdel-Naim, and U. Lindequist, “Cytotoxic isoferulic acidamide from Myricaria germanica (Tamaricaceae),” Plant Signaling and Behavior, vol. 8, no. 1, pp. 33–41, 2013. View at: Google Scholar
  28. A. A. Abdelgawad, “Tamarix nilotica(Ehrenb) Bunge: A Review of Phytochemistry and Pharmacology,” Journal of Microbial and Biochemical Technology, vol. 1, pp. 544–553, 2017. View at: Google Scholar
  29. F. Nicolini, O. Burmistrova, M. T. Marrero et al., “Induction of G2/M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells,” Molecular Carcinogenesis, vol. 53, no. 12, pp. 939–950, 2014. View at: Publisher Site | Google Scholar
  30. K. Y. Orabi, M. S. Abaza, K. A. El Sayed, A. Y. Elnagar, R. Al-Attiyah, and R. P. Guleri, “Selective growth inhibition of human malignant melanoma cells by syringic acid-derived proteasome inhibitors,” Cancer Cell International, vol. 13, no. 1, 2013. View at: Google Scholar
  31. M. S. I. Abaza, M. Afzal, R. J. Al-Attiyah, and R. Guleri, “Methylferulate from Tamarix aucheriana inhibits growth and enhances chemosensitivity of human colorectal cancer cells: Possible mechanism of action,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, article no. 384, 2016. View at: Publisher Site | Google Scholar
  32. A. B. Hmidene, M. Hanaki, K. Murakami, K. Irie, H. Isoda, and H. Shigemori, “Inhibitory activities of antioxidant flavonoids from tamarix gallica on amyloid aggregation related to Alzheimer's and type 2 diabetes diseases,” Biological & Pharmaceutical Bulletin, vol. 40, no. 2, pp. 238–241, 2017. View at: Publisher Site | Google Scholar

Copyright © 2018 N. Alhourani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

897 Views | 393 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.